公开(公告)号：EP1002792A4

公开(公告)日：2002-03-20

申请号：EP98911211

申请日：1998-04-03

申请人： MITSUBISHI PHARMA CORP

发明人： ADACHI KUNITOMO ,  AOKI YOSHIYUKI ,  HANANO TOKUSHI ,  TESHIMA KOJI ,  HOSHINO YUKIO ,  FUJITA TETSURO

IPC分类号： A61K31/00 ,  A61K31/13 ,  A61K31/135 ,  A61P37/00 ,  A61P37/06 ,  C07C20060101 ,  C07C215/00 ,  C07C215/10 ,  C07C215/34 ,  C07C223/00 ,  C07C223/02 ,  C07C225/08 ,  C07C225/16 ,  C07F7/18

CPC分类号： C07C225/16 ,  C07C215/34 ,  C07C223/02 ,  C07F7/1852

摘要： Compounds represented by general formula (I), pharmaceutically acceptable acid addition salts thereof, or hydrates of the same; drugs containing these compounds; medicinal compositions containing these compounds together with pharmaceutically acceptable carriers; and 2-amino-2-(2-(4-(1-hydroxy-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol or 2-amino-2-(2-(4-formylphenyl)ethyl)-propane-1,3-diol optionally protected at the amino and/or hydroxy group or salts thereof, each useful as an intermediate in synthesizing the above compounds. In said formula, R?1, R2, R3 and R4¿ represent each hydrogen or acyl. Because of having little toxicity, high safety and excellent immunosuppressive effects, these compounds are useful as preventives or depressants for rejection reactions in organ or bone marrow transplantations and preventives or remedies for various autoimmune diseases, various allergic diseases, etc.

公开(公告)号：EP1452597A4

公开(公告)日：2006-09-20

申请号：EP02788712

申请日：2002-12-04

申请人： MITSUBISHI PHARMA CORP

发明人： KOUNO TAKAHARU ,  KATSUMURA YASUHIKO

IPC分类号： C12N1/00 ,  C12P21/02 ,  C12P21/08 ,  C12N15/09 ,  C07K1/00 ,  C12P21/00

CPC分类号： C12N1/00 ,  C12P21/02

摘要： A method of producing a protein having free cysteine with the use of a serum-free medium, characterized in that the protein is produced in the activated state a method of producing a protein by culturing in a serum-free medium in accordance with the above method a method of activating a protein having free cysteine which has been produced in the inactivated state and a protein obtained by any of the above methods. This protein shows physicochemical or biological properties comparable to a protein obtained by using a serum medium.

公开(公告)号：EP1413309A4

公开(公告)日：2006-06-07

申请号：EP02749378

申请日：2002-07-29

申请人： MITSUBISHI PHARMA CORP

发明人： OBA KENZO

IPC分类号： A61K31/64 ,  A61K31/66 ,  A61K31/785 ,  A61K31/787 ,  A61P3/06 ,  A61P3/10

CPC分类号： A61K31/64 ,  A61K31/66 ,  A61K31/785 ,  A61K31/787 ,  A61K2300/00

摘要： It is intended to provide drugs for ameliorating postcibal hyperglycemia, drugs for inhibiting an increase in blood glucose level and compositions for preventing or treating diabetics each containing a pharmacologically acceptable anion exchange resin typified by colestimide. Thus, it becomes possible to provide drugs clearly exhibiting an effect of inhibiting an increase in postcibal blood glucose level.

公开(公告)号：EP1256348A4

公开(公告)日：2005-07-27

申请号：EP01904385

申请日：2001-02-13

申请人： MITSUBISHI PHARMA CORP ,  JP NAT INST INFECTIOUS DISEASE

发明人： ITAMI SEIMA ,  SHIBUI TATSUROU ,  SEKI MAKOTO ,  YOTSUMOTO YOSHIHISA ,  MATSUURA YOSHIHARU ,  MIYAMURA TATSUO

IPC分类号： A61K31/737 ,  A61P31/20 ,  C07K16/10 ,  C12N5/02 ,  A61K38/17 ,  A61K39/395 ,  A61K45/00 ,  C12N15/09 ,  G01N33/50 ,  G01N33/53 ,  G01N33/576

CPC分类号： A61K31/737 ,  A61K2039/505 ,  C07K16/109 ,  C07K2317/21 ,  C07K2317/622

摘要： A substance inhibiting the binding of hepatitis C virus E2/NS1 protein to cells with potential infection with hepatitis C virus, cells with the expression of CD81 or CD81. Thus, novel drugs having antiviral effects (inhibition of the infection with HCV, etc.) can be provided.

公开(公告)号：EP1201236A4

公开(公告)日：2005-01-05

申请号：EP00940873

申请日：2000-06-28

申请人： MITSUBISHI PHARMA CORP ,  MATSUMORI AKIRA

发明人： MATSUMORI AKIRA

IPC分类号： A61K31/133 ,  A61K31/137 ,  A61P9/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61P31/22

CPC分类号： A61K31/137

摘要： The present invention aims at providing a pharmaceutical composition for the prophylaxis or treatment, irrespective of the kind of virus, of viral myocarditis or-viral diseases induced by viral myocarditis, by the treatment or prevention of the onset of cytotoxicity in various organs, and a method of the prophylaxis or treatment. The present invention also relates to a pharmaceutical composition for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which contains 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof as an active ingredient. The present invention further relates to a method for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which includes administering an effective amount of the aforementioned compound or a pharmacologically acceptable salt thereof.

公开(公告)号：EP1250929A4

公开(公告)日：2004-12-29

申请号：EP00987665

申请日：2000-12-20

申请人： MITSUBISHI PHARMA CORP

发明人： TAKAHASHI TSUYOSHI ,  FURUSHIMA KOJI ,  MORITA MASANORI ,  TSUJIKAWA MUNEO ,  URAYAMA TAKERU ,  HAMATO NOBUAKI

IPC分类号： A61K35/00 ,  A61L2/00 ,  A61L2/02 ,  A61K35/16 ,  A61K38/36 ,  A61K38/37 ,  A61K38/39 ,  C07K14/75 ,  C07K14/755 ,  C07K14/78

CPC分类号： A61L2/0017 ,  A61K35/00

摘要： Contaminant viruses can be efficiently removed almost without losing the activity of protein by subjecting a plasma protein composition having a high risk of viral contamination to a treatment with a porous membrane having a pore size greater than a single-particle size of the virus, particularly by subjecting a plasma protein composition to a fractionation treatment by precipitation, before the porous membrane treatment. Particularly, a fibrinogen composition substantially free of non-enveloped viruses, Parvovirus among others, can be provided. By the application of the present invention, a safe plasma protein preparation free of viruses can be conveniently provided.

公开(公告)号：EP1186296A4

公开(公告)日：2004-12-22

申请号：EP00931568

申请日：2000-05-25

申请人： MITSUBISHI PHARMA CORP

发明人： KAWASAKI MASAKAZU ,  GOTOH NOBUHARU ,  HAYASHI YOSHIHARU ,  KAWASAKI KAZUYUKI

IPC分类号： A61K31/4164 ,  A61K31/4174 ,  A61K31/4439 ,  A61P25/28 ,  C07D521/00 ,  C07D233/60 ,  C07D401/06

CPC分类号： C07D249/08 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4439 ,  C07D231/12 ,  C07D233/56

摘要： MAG expression promoters containing compounds represented by general formula (I), optically active isomers thereof or pharmaceutically acceptable salts of the same, wherein each symbol is as defined in the description. As an example of the compounds represented by the general formula (I), 4-[α-hydroxy-5-(1-imidazoyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid may be cited. These MAG expression promoters are useful as preventives and/or remedies for diseases of mammals including humans mainly presenting myelin hypoplasia and, in its turn, myelin sheath hypoplasia or myelin sheath destruction

公开(公告)号：EP1346724A4

公开(公告)日：2004-11-17

申请号：EP01271879

申请日：2001-12-25

申请人： MITSUBISHI PHARMA CORP

发明人： MORIOKA M ,  UBASAWA M ,  ARAI M

IPC分类号： A61K31/706 ,  A61K31/7068 ,  A61K31/7072 ,  A61P1/16 ,  A61P31/14 ,  C07H19/06 ,  C07H19/10 ,  C07H19/073 ,  C07H19/12

CPC分类号： C07H19/06 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7072 ,  C07H19/10

摘要： Excellent remedies for hepatitis C which contain as the active ingredients a 3'-deoxy-3'-fluorouridine derivative and a 1-(3'-deoxy-3'-fluoro- beta -L-ribofuranosyl)uracil derivative and show little side effects.

公开(公告)号：EP1419771A4

公开(公告)日：2004-11-03

申请号：EP02762812

申请日：2002-08-21

申请人： MITSUBISHI PHARMA CORP

发明人： ISHII S ,  SASAKI K ,  UENO H

IPC分类号： A61P9/00 ,  A61P9/10 ,  A61P43/00 ,  C07D277/34 ,  C07D417/12 ,  A61K31/426

CPC分类号： C07D417/12 ,  C07D277/34

摘要： A preventive and/or remedy for diseases attributable to arteriosclerotic activity, such as ischemic heart diseases and acute coronary arterial syndrome, which contains as an active ingredient a compound represented by the following general formula (I): (I) or a pharmaceutically acceptable salt of the compound. It is a novel preventive and/or remedy for diseases attributable to arteriosclerotic activity and is more potent than known drugs. (In the formula, A represents a thiazolidinedione ring, etc.; -X- represents -O- or -S-; =Y- represents =N- or =CR5-; R1, R2, R3, R4, R5, and R6 each independently represents hydrogen, etc.; n is an integer of 0 to 3; and the dotted line indicates that the linkage may be a double bond.)

公开(公告)号：EP1283262A4

公开(公告)日：2004-07-14

申请号：EP01917711

申请日：2001-03-30

申请人： MITSUBISHI PHARMA CORP

发明人： MITSUMORI CRISTINA ,  MORIKAWA NORIYUKI ,  HAYASHI KOJI ,  NAGAHARI KENJI ,  OTA TOSHIO ,  HIO YURI ,  NISHIKAWA TETSUO ,  ISOGAI TAKAO ,  KAWASAKI MASAKAZU ,  HASHIMOTO KENJI ,  KISHIMOTO TOSHIMITSU

IPC分类号： A61K38/00 ,  C07K14/47 ,  C12N15/12 ,  C07K14/48 ,  C12N15/67 ,  C12Q1/02

CPC分类号： C07K14/4705 ,  A61K38/00 ,  G01N2333/48 ,  G01N2500/10

摘要： It is found out that the culture supernatant of COS cells wherein PSEC56 gene is expressed has a neurite outgrowth effect. It is further clarified that this activity of the culture supernatant is brought about by NGF contained therein. Thus, it is found out that PSEC56 is usable as a neurotrophic factor expression-inducing agent and that the induction system of the NGF is applicable to the development of drugs for neural diseases.